Tesamorelin
Tesamorelin is a stabilized GHRH analogue and one of the few GH-axis peptides with a real pharmaceutical identity rather than a pure research-peptide reputation. It stimulates pituitary GH release and downstream IGF-1 strongly enough to be clinically relevant, and it is best known for reducing visceral fat in the HIV lipodystrophy setting where it was originally developed.
In performance circles, tesamorelin gets attention from users who want a more legitimate GHRH option and care specifically about midsection fat distribution, waistline trend, and GH-axis support without the appetite spike and rougher feel common to the GHRP side of the family.
People choose tesamorelin when they want a GHRH analogue with a stronger legitimacy story and a clearer target than most peptide stacks. The appeal is usually central fat distribution, waistline trend, and visceral-fat reduction rather than trying to force a dramatic muscle-building effect out of a peptide.
- Official tesamorelin is supplied as a lyophilized product that must be reconstituted exactly as directed by the kit or manufacturer.
- Standard use is 2 mg injected subcutaneously once daily, usually into abdominal fat while rotating sites. Most users stay near that range rather than escalating aggressively.
- Expect slow changes across weeks to months. The practical target is visceral-fat trend and waistline change, not an immediate cosmetic transformation.
- Monitor fasting glucose, HbA1c, edema, and IGF-1 if use becomes prolonged or aggressive.
This is a slow compound. If it works, the feedback is usually gradual change in waistline, body-composition trend, and sometimes a general sense that recovery is a bit better. It is not the kind of peptide that usually produces a loud day-to-day effect.
Use context
Tesamorelin stands out because it is an actual prescription GHRH analogue, not just another grey-market peptide people talk up on forums. The practical reason it gets attention is pretty specific: it has a real visceral-fat use case, and that is a different conversation from the usual “GH peptides for recovery and recomposition” pitch.
It also sits on a different part of the spectrum than compounds like GHRP-2 or Ipamorelin. Tesamorelin is less about chasing a noticeable pulse and more about using a cleaner, more pharmaceutical GH-axis signal for a slower body-composition objective.
The biggest mistake is treating tesamorelin like a generic fat-loss peptide and expecting rapid visible change. The second is pushing the dose around as if more must be better, when the real issues tend to be glucose tolerance, edema, and whether the user even has a visceral-fat problem worth targeting in the first place.
Compared with Ipamorelin or GHRP-2, tesamorelin is less about appetite or pulse feel and more about a specific visceral-fat use case. Compared with CJC-1295, it has a more pharmaceutical identity and a narrower practical role. Compared with direct hGH, it is usually milder, less dramatic, and more dependent on whether visceral fat is actually the problem being targeted.
Injection-site irritation, edema, joint tightness, and numb-hand or carpal-tunnel-like symptoms in some users
Higher fasting glucose or worse glucose tolerance if the user is already metabolically fragile
fasting glucose / HbA1c
IGF-1
waist circumference and bodyweight trend
edema or hand numbness
Poor glucose control without monitoring
Users expecting fast subcutaneous fat loss or a dramatic GH feel from a once-daily GHRH analogue